文献速递临床试验与 GCP

伐尼克兰联合尼古丁贴片及延长疗程对戒烟效果的影响:一项随机临床试验

Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial.
PubMed 文献 · JAMA · 2021-01-01

该双盲2×2析因随机临床试验纳入1251名每日吸烟≥5支的成人,比较伐尼克兰联合尼古丁贴片与单药、以及12周与24周疗程对52周戒断率的影响。结果显示联合治疗与单药、延长疗程与标准疗程在52周7天点戒断率上均无显著差异,不支持联合用药或延长疗程。

要点

  • 伐尼克兰联合尼古丁贴片与单药相比,52周戒断率无显著差异。
  • 24周延长疗程与12周标准疗程相比,52周戒断率无显著差异。
  • 药物类型与疗程之间无显著交互作用。

核心结论

  • 在每日吸烟≥5支的成人中,伐尼克兰联合尼古丁贴片与单药、以及24周与12周疗程在52周7天点戒断率上均无显著差异。
  • 研究结果不支持使用联合治疗或延长治疗疗程。

研究设计与样本

  • 双盲2×2析因随机临床试验,于2017年11月11日至2020年7月9日在美国威斯康星州麦迪逊市和密尔沃基市各一家研究诊所开展。
  • 共邀请5836名成人参与,最终随机分配1251名每日吸烟≥5支者。
  • 参与者随机分为四组:伐尼克兰单药12周(n=315)、伐尼克兰联合尼古丁贴片12周(n=314)、伐尼克兰单药24周(n=311)、伐尼克兰联合尼古丁贴片24周(n=311)。
  • 所有参与者均接受戒烟咨询。

主要发现

  • 随机化患者平均年龄49.1岁(SD 11.9),女性675人(54.0%);751人(60.0%)完成治疗,881人(70.4%)提供最终随访。
  • 24周组与12周组52周主要结局发生率分别为24.8%(154/622)与24.3%(153/629),风险差-0.4%(95%CI -5.2%至4.3%),OR 1.01(95%CI 0.89-1.15)。
  • 联合治疗组与单药组52周主要结局发生率分别为24.3%(152/625)与24.8%(155/626),风险差0.4%(95%CI -4.3%至5.2%),OR 0.99(95%CI 0.87-1.12)。
  • 四组恶心发生率范围为24.0%至30.9%,失眠发生率范围为24.4%至30.5%。

临床怎么用

  • 对于每日吸烟≥5支的成人,伐尼克兰联合尼古丁贴片或延长至24周疗程未显示额外戒烟获益。
  • 临床可继续采用伐尼克兰单药标准12周疗程作为戒烟治疗方案之一。

局限性

  • 研究仅在美国威斯康星州两家诊所开展,外推性可能受限。
  • 完成治疗者占60.0%,提供最终随访者占70.4%,存在失访偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Smoking cessation medications are routinely used in health care. Research suggests that combining varenicline with the nicotine patch, extending the duration of varenicline treatment, or both, may increase cessation effectiveness. OBJECTIVE: To compare combinations of varenicline plus the nicotine or placebo patch vs combinations used for either 12 weeks (standard duration) or 24 weeks (extended duration). DESIGN, SETTINGS, AND PARTICIPANTS: Double-blind, 2 × 2 factorial randomized clinical trial conducted from November 11, 2017, to July 9, 2020, at 1 research clinic in Madison, Wisconsin, and at 1 clinic in Milwaukee, Wisconsin. Of the 5836 adults asked to participate in the study, 1251 who smoked 5 cigarettes/d or more were randomized. INTERVENTIONS: All participants received cessation counseling and were randomized to 1 of 4 medication groups: varenicline monotherapy for 12 weeks (n = 315), varenicline plus nicotine patch for 12 weeks (n = 314), varenicline monotherapy for 24 weeks (n = 311), or varenicline plus nicotine patch for 24 weeks (n = 311). MAIN OUTCOMES AND MEASURES: The primary outcome was carbon monoxide-confirmed self-reported 7-day point prevalence abstinence at 52 weeks. RESULTS: Among 1251 patients who were randomized (mean [SD] age, 49.1 [11.9] years; 675 [54.0%] women), 751 (60.0%) completed treatment and 881 (70.4%) provided final follow-up. For the primary outcome, there was no significant interaction between the 2 treatment factors of medication type and medication duration (odds ratio [OR], 1.03 [95% CI, 0.91 to 1.17]; P = .66). For patients randomized to 24-week vs 12-week treatment duration, the primary outcome occurred in 24.8% (154/622) vs 24.3% (153/629), respectively (risk difference, -0.4% [95% CI, -5.2% to 4.3%]; OR, 1.01 [95% CI, 0.89 to 1.15]). For patients randomized to varenicline combination therapy vs varenicline monotherapy, the primary outcome occurred in 24.3% (152/625) vs 24.8% (155/626), respectively (risk difference, 0.4% [95% CI, -4.3% to 5.2%]; OR, 0.99 [95% CI, 0.87 to 1.12]). Nausea occurrence ranged from 24.0% to 30.9% and insomnia occurrence ranged from 24.4% to 30.5% across the 4 groups. CONCLUSIONS AND RELEVANCE: Among adults smoking 5 cigarettes/d or more, there were no significant differences in 7-day point prevalence abstinence at 52 weeks among those treated with combined varenicline plus nicotine patch therapy vs varenicline monotherapy, or among those treated for 24 weeks vs 12 weeks. These findings do not support the use of combined therapy or of extended treatment duration. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03176784.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Baker TB, Piper ME, Smith SS, et al. Effects of Combined Varenicline With Nicotine Patch and of Extended Treatment Duration on Smoking Cessation: A Randomized Clinical Trial. JAMA. 2021. PMID: 34665204. doi:10.1001/jama.2021.15333

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。